LH

Labcorp Holdings Inc.

Healthcare
257.70 +0.83 +0.32% Market Closed
2026-06-02 • USD

Key Metrics

Market Cap 21.13B
EV —
Shares Out 82.00M
Revenue (ttm) 14.14B
Net Income 941.50M
Beta —
P/E 20.90
Forward P/E —
EPS (ttm) $11.29
P/S —
P/B 2.43
P/FCF —
P/C —
EV/Sales —
EV/EBITDA —
ROA 4.93%
ROE 10.95%
ROIC —
Gross Margin 28.83%
Oper. Margin 10.18%
Profit Margin 6.66%
Debt/Eq 0.82
LT Debt/Eq 40.06%
Quick Ratio —
Current Ratio 1.73
Book/sh 106.06
Cash/sh 11.92
Div Yield 1.12%
Div TTM $2.88
Payout Ratio 25.51%
SMA20 0.39%
SMA50 -1.78%
SMA200 -3.92%
Volume 378,904
Avg Volume 652.82K
Rel Volume —
Perf Week -0.91%
Perf Month 0.22%
Perf Quarter -6.60%
Perf Half Y -0.27%
Perf YTD 2.72%
Perf Year 2.20%
Perf 3Y 37.74%
Perf 5Y 12.63%

Factor Lens

Seasonal Performance

Dividends

Per-share amounts adjusted for stock splits.

Last Dividend $0.7200
TTM Yield 1.12%
TTM Amount $2.88
Payout Ratio 25.51%
3-Yr Growth (CAGR) 10.06%
5-Yr Growth (CAGR) —

Last 12 Payouts

Period Ex-Date Amount / Share
Q1 2026 ~2026-03-31 $0.7200
Q4 2025 ~2025-12-30 $0.7200
Q3 2025 ~2025-09-30 $0.7200
Q2 2025 ~2025-06-30 $0.7200
Q1 2025 ~2025-03-31 $0.7200
Q3 2024 ~2024-09-30 $0.7200
Q2 2024 ~2024-06-30 $0.7200

Financial Trends

Revenue & Net Income

Earnings Per Share

Margins

Cash Flow

Company Overview

Labcorp Holdings Inc. is a global leader of innovative and comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. The Company provides insights and accelerates innovations to improve health and improve lives through its unparalleled diagnostics and drug development laboratory capabilities. During 2025, the Company's nearly 71,000 employees served clients in approximately 100 countries and performed more than 750 million tests for patients around the world. In addition, the Company provided support for more than 85% of the new drugs and therapeutic products approved in 2025 by the FDA. The Company operates two main business segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Company's strength in science, technology, and innovation, as well as its global scale, powers its continued success and enables it to play a leading role in advancing healthcare across the globe. Strategic priorities include being a partner of choice for health systems and regional laboratories, and leading in the development, licensing, and scaling of specialty testing across oncology, neurology, autoimmune disease, and women's health areas.

Name
Labcorp Holdings Inc.
Industry
Diagnostics & Research
CEO
Adam H. Schechter · Chairman, President, and Chief Executive Officer
Employees
71,000 as of 2025-12-31
IPO Date
2018-10-18
Phone
(336) 229-1127
Address
358 South Main Street, Burlington, NC 27215
Website
http://www.labcorp.com

Key Executives

Name Title FY Pay
Peter M. Neupert Director —
Paul B. Rothman, M.D. Director —
Kerrii B. Anderson Director —
Garheng Kong, M.D., Ph.D. Vice Chairman and Lead Independent Director —
Adam H. Schechter Chairman, President, and Chief Executive Officer —

Latest News